AstraZeneca has acquired rights to a Sino Biopharmaceutical molecule aimed at chronic obstructive pulmonary disease, in a move designed to extend its respiratory pipeline with a dual-mechanism approach. The licensed candidate is positioned as a potential competitor to a strategy acquired by Merck in a large deal last year for a new COPD therapy. The deal centers on a drug concept that uses two mechanisms for disease modification, a strategy AstraZeneca is increasingly using to strengthen differentiating profiles. Financial and commercial terms were not detailed in the provided report, but the transaction underscores continued cross-border partnering for late-stage-ready assets. For AstraZeneca, the China-sourced molecule represents an attempt to tighten portfolio coverage in COPD at a time when differentiation increasingly hinges on mechanism and patient stratification. For Sino Biopharmaceutical, it adds a major partner for further development and commercialization pathways.